Skip to main content
Livermore
Livermore
ZHEN

VR Adviser, LLC

SEC CIK
0001615982
Latest filing
Aug 14, 2026

Holdings in Q1 2024

Holdings as of Mar 31, 2024, filed May 15, 2024. Long positions only; changes compare share counts with Q4 2023.

Institution overview
Positions
38
+2 vs. Q4 2023
Portfolio value
$2.10B
+$644.1M (+44.2%) vs. Q4 2023
Filed
May 15, 2024
SEC
Holdings of VR Adviser, LLC in Q1 2024
SecurityClassSharesValue% of portfolioShare changeActionHistory
OLMAOlema Pharmaceuticals, Inc.COM77,042$872.1K<0.1%00.0%UnchangedHistory
EYPTEyePoint, Inc.COM NEW250,000$5.17M0.2%00.0%UnchangedHistory
SLRNACELYRIN, Inc.COM937,113$6.33M0.3%00.0%UnchangedHistory
MLYSMineralys Therapeutics, Inc.COM555,554$7.17M0.3%+555,554NewHistory
TNYATenaya Therapeutics, Inc.COM1,555,556$8.14M0.4%+1,555,556NewHistory
TRVITrevi Therapeutics, Inc.COM3,422,675$11.8M0.6%+2780.0%AddedHistory
IPSCCentury Therapeutics, Inc.COM3,405,133$14.2M0.7%+3,405,133NewHistory
CGONCG Oncology, Inc.COM350,000$15.4M0.7%+350,000NewHistory
LYRALyra Therapeutics, Inc.COM2,576,093$16.0M0.8%+5000.0%AddedHistory
IMTXImmatics N.V.SHS1,750,000$18.4M0.9%+1,750,000NewHistory
ABVXAbivax S.A.SPONSORED ADS1,345,780$19.2M0.9%+347,210+34.8%AddedHistory
CELCCelcuity Inc.COM970,000$21.0M1.0%−915,538−48.6%ReducedHistory
ADVMAdverum Biotechnologies, Inc.COM NEW1,556,419$22.0M1.0%+1,041,664+202.4%AddedConverted for a 1-for-10 splitHistory
TERNTerns Pharmaceuticals, Inc.COM3,410,058$22.4M1.1%−1,087,059−24.2%ReducedHistory
AQSTAquestive Therapeutics, Inc.COM5,555,555$23.7M1.1%+5,555,555NewHistory
TSHATaysha Gene Therapies, Inc.COM SHS9,000,000$25.8M1.2%−1,412,872−13.6%ReducedHistory
ARVNArvinas, Inc.COM627,788$25.9M1.2%00.0%UnchangedHistory
CABACabaletta Bio, Inc.COM1,563,952$26.7M1.3%−1,000,000−39.0%ReducedHistory
EWTXEdgewise Therapeutics, Inc.COM1,818,182$33.2M1.6%+1,818,182NewHistory
COGTCogent Biosciences, Inc.COM5,129,167$34.5M1.6%+445,000+9.5%AddedHistory
HLVXHilleVax, Inc.COM2,075,000$34.5M1.6%00.0%UnchangedHistory
PRAXPraxis Precision Medicines, Inc.COM NEW706,126$43.1M2.0%+352,500+99.7%AddedHistory
ENGNenGene Therapeutics Inc.COM2,565,841$43.5M2.1%+2,565,841NewHistory
MRSNMersana Therapeutics, Inc.COM11,328,000$50.7M2.4%00.0%UnchangedHistory
ATXSAstria Therapeutics, Inc.COM3,608,645$50.8M2.4%+382,839+11.9%AddedHistory
ORICOric Pharmaceuticals, Inc.COM4,394,527$60.4M2.9%+1,966,142+81.0%AddedHistory
APLTApplied Therapeutics, Inc.COM9,075,000$61.7M2.9%+2,825,000+45.2%AddedHistory
DYNDyne Therapeutics, Inc.COM2,173,913$61.7M2.9%00.0%UnchangedHistory
DNTHDianthus Therapeutics, Inc.COM2,094,373$62.8M3.0%+1,166,667+125.8%AddedHistory
VRDNViridian Therapeutics, Inc.COM3,882,671$68.0M3.2%+480.0%AddedHistory
ELVNEnliven Therapeutics, Inc.COM4,026,331$70.8M3.4%+1,071,429+36.3%AddedHistory
KALVKalVista Pharmaceuticals, Inc.COM6,249,731$74.1M3.5%+2,157,000+52.7%AddedHistory
PHVSPharvaris N.V.COM3,395,606$78.5M3.7%00.0%UnchangedHistory
MRUSMerus N.V.COM1,790,214$80.6M3.8%−358,000−16.7%ReducedHistory
SYRESpyre Therapeutics, Inc.COM NEW2,171,782$82.4M3.9%−200,932−8.5%ReducedHistory
OCULOcular Therapeutix, IncCOM12,762,462$116.1M5.5%+4,986,702+64.1%AddedHistory
FDMT4D Molecular Therapeutics, Inc.COM4,400,000$140.2M6.7%+975,969+28.5%AddedHistory
APGEApogee Therapeutics, Inc.COM8,493,321$564.4M26.8%00.0%UnchangedHistory

Sold out since Q4 2023 (6)

Positions held at the end of Q4 2023 that are gone from this filing.

Positions of VR Adviser, LLC sold out since Q4 2023
SecurityClassShares in Q4 2023Value in Q4 2023% of portfolio in Q4 2023History
RYZBRayzeBio, Inc.COM4,030,471$250.6M17.2%History
AMAMAmbrx Biopharma, Inc.COM2,070,000$29.5M2.0%History
RYTMRhythm Pharmaceuticals, Inc.COM495,983$22.8M1.6%History
SVRASavara IncCOM3,500,000$16.4M1.1%History
GHRSGH Research PLCORDINARY SHARES1,318,327$7.65M0.5%History
MISTMilestone Pharmaceuticals Inc.COM925,048$1.54M0.1%History